Nicole Mayer-Hamblett1,2,3, George Retsch-Bogart4, Margaret Kloster3, Frank Accurso5,6, Margaret Rosenfeld1,3, Gary Albers7, Philip Black8, Perry Brown9, AnneMarie Cairns10, Stephanie D Davis11,12, Gavin R Graff13,14, Gwendolyn S Kerby5,6, David Orenstein15, Rachael Buckingham3, Bonnie W Ramsey1,2. 1. 1 Department of Pediatrics and. 2. 3 Department of Biostatistics, University of Washington, Seattle, Washington. 3. 2 Seattle Children's Hospital, Seattle, Washington. 4. 4 Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina. 5. 5 Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado. 6. 6 Children's Hospital Colorado, Aurora, Colorado. 7. 7 Department of Pediatrics, Saint Louis University School of Medicine, Saint Louis, Missouri. 8. 8 Children's Mercy Hospital, Kansas City, Missouri. 9. 9 St. Luke's Regional Medical Center, Boise, Idaho. 10. 10 Maine Medical Center, Portland, Maine. 11. 11 Indiana University Hospital, Indianapolis, Indiana. 12. 12 James Whitcomb Riley Hospital for Children, Indianapolis, Indiana. 13. 13 Hershey Medical Center, Hershey, Pennsylvania. 14. 14 Penn State Children's Hospital, Hershey, Pennsylvania; and. 15. 15 UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
RATIONALE: New isolation of Pseudomonas aeruginosa (Pa) is generally treated with inhaled antipseudomonal antibiotics such as tobramycin inhalation solution (TIS). A therapeutic approach that complements traditional antimicrobial therapy by reducing the risk of pulmonary exacerbation and inflammation may ultimately prolong the time to Pa recurrence. OBJECTIVES: To test the hypothesis that the addition of azithromycin to TIS in children with cystic fibrosis and early Pa decreases the risk of pulmonary exacerbation and prolongs the time to Pa recurrence. METHODS: The OPTIMIZE (Optimizing Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis) trial was a multicenter, double-blind, randomized, placebo-controlled, 18-month trial in children with CF, 6 months to 18 years of age, with early Pa. Azithromycin or placebo was given 3× weekly with standardized TIS. MEASUREMENTS AND MAIN RESULTS: The primary endpoint was the time to pulmonary exacerbation requiring antibiotics and the secondary endpoint was the time to Pa recurrence, in addition to other clinical and safety outcomes. A total of 221 participants (111 placebo, 110 azithromycin) out of a planned 274 were enrolled. Enrollment was stopped early by the NHLBI because the trial had reached the prespecified interim boundary for efficacy. The risk of pulmonary exacerbation was reduced by 44% in the azithromycin group as compared with the placebo group (hazard ratio, 0.56; 95% confidence interval, 0.37-0.83; P = 0.004). Weight increased by 1.27 kg in the azithromycin group compared with the placebo group (95% confidence interval, 0.01-2.52; P = 0.046). No significant differences were seen in microbiological or other clinical or safety endpoints. CONCLUSIONS: Azithromycin was associated with a significant reduction in the risk of pulmonary exacerbation and a sustained improvement in weight, but had no impact on microbiological outcomes in children with early Pa. Clinical trial registered with clinicaltrials.gov (NCT02054156).
RATIONALE: New isolation of Pseudomonas aeruginosa (Pa) is generally treated with inhaled antipseudomonal antibiotics such as tobramycin inhalation solution (TIS). A therapeutic approach that complements traditional antimicrobial therapy by reducing the risk of pulmonary exacerbation and inflammation may ultimately prolong the time to Pa recurrence. OBJECTIVES: To test the hypothesis that the addition of azithromycin to TIS in children with cystic fibrosis and early Pa decreases the risk of pulmonary exacerbation and prolongs the time to Pa recurrence. METHODS: The OPTIMIZE (Optimizing Treatment for Early Pseudomonas aeruginosa Infection in Cystic Fibrosis) trial was a multicenter, double-blind, randomized, placebo-controlled, 18-month trial in children with CF, 6 months to 18 years of age, with early Pa. Azithromycin or placebo was given 3× weekly with standardized TIS. MEASUREMENTS AND MAIN RESULTS: The primary endpoint was the time to pulmonary exacerbation requiring antibiotics and the secondary endpoint was the time to Pa recurrence, in addition to other clinical and safety outcomes. A total of 221 participants (111 placebo, 110 azithromycin) out of a planned 274 were enrolled. Enrollment was stopped early by the NHLBI because the trial had reached the prespecified interim boundary for efficacy. The risk of pulmonary exacerbation was reduced by 44% in the azithromycin group as compared with the placebo group (hazard ratio, 0.56; 95% confidence interval, 0.37-0.83; P = 0.004). Weight increased by 1.27 kg in the azithromycin group compared with the placebo group (95% confidence interval, 0.01-2.52; P = 0.046). No significant differences were seen in microbiological or other clinical or safety endpoints. CONCLUSIONS: Azithromycin was associated with a significant reduction in the risk of pulmonary exacerbation and a sustained improvement in weight, but had no impact on microbiological outcomes in children with early Pa. Clinical trial registered with clinicaltrials.gov (NCT02054156).
Authors: Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey Journal: Pediatr Pulmonol Date: 2011-08-09
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard Journal: JAMA Date: 2005-02-02 Impact factor: 56.272
Authors: Miriam M Treggiari; George Retsch-Bogart; Nicole Mayer-Hamblett; Umer Khan; Michal Kulich; Richard Kronmal; Judy Williams; Peter Hiatt; Ronald L Gibson; Terry Spencer; David Orenstein; Barbara A Chatfield; Deborah K Froh; Jane L Burns; Margaret Rosenfeld; Bonnie W Ramsey Journal: Arch Pediatr Adolesc Med Date: 2011-09
Authors: Ranjani Somayaji; Renee Russell; Jonathan D Cogen; Cristopher H Goss; Sarah E Nick; Milene T Saavedra; Jennifer L Taylor-Cousar; Jerry A Nick; Dave P Nichols Journal: Ann Am Thorac Soc Date: 2019-07
Authors: Dustin R Long; Daniel J Wolter; Michael Lee; Mimi Precit; Kathryn McLean; Elizabeth Holmes; Kelsi Penewit; Adam Waalkes; Lucas R Hoffman; Stephen J Salipante Journal: Am J Respir Crit Care Med Date: 2021-05-01 Impact factor: 21.405
Authors: Rosa María Girón Moreno; Marta García-Clemente; Layla Diab-Cáceres; Adrián Martínez-Vergara; Miguel Ángel Martínez-García; Rosa Mar Gómez-Punter Journal: Antibiotics (Basel) Date: 2021-04-23
Authors: Jonathan D Cogen; Anna V Faino; Frankline Onchiri; Ronald L Gibson; Lucas R Hoffman; Matthew P Kronman; Margaret Rosenfeld; David P Nichols Journal: Ann Am Thorac Soc Date: 2021-02
Authors: Amalia S Magaret; Jack Salerno; Jason F Deen; Margaret Kloster; Nicole Mayer-Hamblett; Bonnie W Ramsey; Dave P Nichols Journal: J Cyst Fibros Date: 2020-11-24 Impact factor: 5.482
Authors: Jonathan D Cogen; Frankline M Onchiri; Nicole Mayer Hamblett; Ronald L Gibson; Wayne J Morgan; Margaret Rosenfeld Journal: Clin Infect Dis Date: 2021-09-15 Impact factor: 9.079